Spots Global Cancer Trial Database for clinical stage iii cutaneous melanoma ajcc v8

Every month we try and update this database with for clinical stage iii cutaneous melanoma ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma	NCT03033576	Clinical Stage ... Clinical Stage ... Melanoma of Unk... Mucosal Melanom... Unresectable Cu... Unresectable Me...	Ipilimumab Nivolumab	18 Years -	National Cancer Institute (NCI)
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma	NCT03727789	Advanced Cutane... Advanced Sarcom... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... Recurrent Sarco... Stage III Soft ... Stage IIIA Soft... Stage IIIB Soft... Stage IV Soft T...	FACT Complex-ta...	18 Years -	Roswell Park Cancer Institute
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma	NCT03865212	Clinical Stage ... Clinical Stage ... Metastatic Chor... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Me...	Recombinant Ves...	18 Years -	Mayo Clinic
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	NCT01989585	Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study	NCT04593277	Clinical Stage ... Clinical Stage ... Clinical Stage ... Hematopoietic a... Invasive Malign... Leukemia Lymphoma Malignant Solid... Sarcoma Stage I Colorec... Stage II Colore... Stage III Color... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Thyroid Gland C...	Internet Mobile... Internet-Based ... Questionnaire A... Supportive Care Informational I...	18 Years -	Fred Hutchinson Cancer Center
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors	NCT04990726	Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Melanoma, Stage... Melanoma Stage ...	Assessment Biospecimen Col... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Bone Loss in Melanoma Survivors Receiving Immunotherapy	NCT04516122	Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Biospecimen Col... Dual X-ray Abso...	40 Years -	M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	NCT04940299	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Malignant Solid... Metastatic Blad... Metastatic Blad... Metastatic Lung... Metastatic Mela... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Uret... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Lung ... Stage IVB Lung ... Unresectable Me...	Ipilimumab Nivolumab Tocilizumab	18 Years -	M.D. Anderson Cancer Center
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma	NCT05907512	Clinical Stage ... Clinical Stage ...	Endostar Toripalimab	18 Years - 75 Years	Fudan University
National Cancer Institute "Cancer Moonshot Biobank"	NCT04314401	Acute Myeloid L... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Lung Non-Small ... Lung Small Cell... Malignant Solid... Metastatic Pros... Multiple Myelom... Stage III Lung ... Stage III Ovari... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVB Prost...	Biospecimen Col... Medical Chart R...	13 Years -	National Cancer Institute (NCI)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	NCT02224781	Clinical Stage ... Clinical Stage ... Metastatic Mela... Recurrent Melan... Unresectable Me...	Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Echocardiograph... Ipilimumab Multigated Acqu... Nivolumab Quality-of-Life... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	NCT04375527	Clinical Stage ... Clinical Stage ... Locally Advance... Metastatic Cuta... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Cu...	Binimetinib Nivolumab Questionnaire A...	18 Years -	Jonsson Comprehensive Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma	NCT03554083	Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Atezolizumab Cobimetinib Tiragolumab Vemurafenib	18 Years -	Mayo Clinic
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
National Cancer Institute "Cancer Moonshot Biobank"	NCT04314401	Acute Myeloid L... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Lung Non-Small ... Lung Small Cell... Malignant Solid... Metastatic Pros... Multiple Myelom... Stage III Lung ... Stage III Ovari... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVB Prost...	Biospecimen Col... Medical Chart R...	13 Years -	National Cancer Institute (NCI)
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	NCT02595866	AIDS-Related No... Clinical Stage ... Clinical Stage ... Hepatocellular ... HIV Infection Kaposi Sarcoma Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Non-Hodgkin Lym... Recurrent Class... Recurrent Malig... Refractory Clas... Refractory Mali... Stage III Lung ... Stage IV Lung C... Unresectable Me...	Antiretroviral ... Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer	NCT03819296	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab	18 Years -	M.D. Anderson Cancer Center
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	NCT04356729	Clinical Stage ... Stage IV Melano... Unresectable St... Unresectable St...	Atezolizumab Bevacizumab	18 Years -	Dana-Farber Cancer Institute
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	NCT02506153	Clinical Stage ... Clinical Stage ... Metastatic Cuta... Metastatic Muco... Metastatic Non-... Non-Cutaneous M... Recurrent Cutan... Recurrent Mucos... Recurrent Non-C...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Pembrolizumab Positron Emissi... Quality-of-Life... Recombinant Int...	18 Years -	National Cancer Institute (NCI)
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma	NCT04708418	Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi... Surgical Proced... VLP-encapsulate...	18 Years -	National Cancer Institute (NCI)
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study	NCT04645680	Clinical Stage ... Clinical Stage ... Metastatic Mela... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dietary Interve... Dietary Interve... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer	NCT04067960	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Biliary Tract C... Clinical Stage ... Clinical Stage ... Malignant Brain... Malignant Genit... Malignant Solid... Pancreatobiliar... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Color... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IIIA Colo... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIB Colo... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Colore... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IVA Color... Stage IVA Ovari... Stage IVA Pancr... Stage IVA Prost... Stage IVB Color... Stage IVB Ovari... Stage IVB Pancr... Stage IVB Prost... Stage IVC Color...	Biospecimen Col... Genetic Testing Quality-of-Life... Questionnaire A...	-	Mayo Clinic
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	NCT04356729	Clinical Stage ... Stage IV Melano... Unresectable St... Unresectable St...	Atezolizumab Bevacizumab	18 Years -	Dana-Farber Cancer Institute
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study	NCT05393713	Clinical Stage ... Melanoma Metastatic Mela... Recurrent Metas...	Anti-PD-L1 Mono... Punch Biopsy	18 Years -	Mayo Clinic
National Cancer Institute "Cancer Moonshot Biobank"	NCT04314401	Acute Myeloid L... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Lung Non-Small ... Lung Small Cell... Malignant Solid... Metastatic Pros... Multiple Myelom... Stage III Lung ... Stage III Ovari... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVB Prost...	Biospecimen Col... Medical Chart R...	13 Years -	National Cancer Institute (NCI)
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer	NCT03819296	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab	18 Years -	M.D. Anderson Cancer Center
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	NCT03816332	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Mela... Metastatic Merk... Metastatic Skin... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ba... Unresectable Me... Unresectable Me...	Ipilimumab Nivolumab Prednisone Tacrolimus	18 Years -	National Cancer Institute (NCI)
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma	NCT03727789	Advanced Cutane... Advanced Sarcom... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... Recurrent Sarco... Stage III Soft ... Stage IIIA Soft... Stage IIIB Soft... Stage IV Soft T...	FACT Complex-ta...	18 Years -	Roswell Park Cancer Institute
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	NCT05896839	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Carc... Metastatic Mela... Metastatic Merk... Metastatic Skin... Unresectable Ba... Unresectable Me... Unresectable Me... Unresectable Sk...	Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Kidney Biopsy Magnetic Resona... Nivolumab Prednisone Sirolimus	18 Years -	National Cancer Institute (NCI)
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma	NCT03698019	Acral Lentigino... Clinical Stage ... Clinical Stage ... Mucosal Melanom...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Bone Loss in Melanoma Survivors Receiving Immunotherapy	NCT04516122	Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Biospecimen Col... Dual X-ray Abso...	40 Years -	M.D. Anderson Cancer Center
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families	NCT03677739	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... First Degree Re... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Informational I... Informational I... Survey Administ...	18 Years - 80 Years	Rutgers, The State University of New Jersey
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types	NCT06075524	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Lung... Metastatic Mali... Metastatic Mela... Stage III Lung ... Stage IV Lung C...	Biospecimen Col... Electronic Heal...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: